Ovarian Suppression for Younger Women With HR+ Breast Cancer
Prudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.
Clinical Pearls
Prudence Francis, MD, from the Peter MacCallum Cancer Centre in Victoria, Australia, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with hormone receptor-positive breast cancer.
- Younger women with HR-positive breast cancer have a higher risk of recurrence than those over 35.
- SOFT compared tamoxifen plus ovarian function suppression versus tamoxifen alone. The addition of ovarian function suppression reduced recurrence of breast cancer in higher-risk young women who did not reach menopause after chemotherapy.
- The value of adding ovarian function suppression had previously been uncertain. The findings from this study suggest that the combination could become the standard of care.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
